Guardant Health

Guardant Health is a pioneer in non-invasive cancer diagnostics and the first company to commercialize a comprehensive genomic liquid biopsy. The Company's proprietary digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. 

Company Growth (employees)
Redwood City, US
Size (employees)
225 (est)+6%
Guardant Health was founded in 2012 and is headquartered in Redwood City, US

Key People at Guardant Health

Helmy Eltoukhy

Helmy Eltoukhy

Michael Wiley

Michael Wiley

Richard Lanman

Richard Lanman

Chief Medical Officer
AmirAli Talasaz

AmirAli Talasaz

President & CTO

Guardant Health Office Locations

Guardant Health has offices in Redwood City and The Woodlands
Redwood City, US (HQ)
505 Penobscot Dr

Guardant Health Data and Metrics

Summary Metrics

Guardant Health's latest funding round in May 2017 was reported to be $360 m. In total, Guardant Health has raised $590 m

Traffic Overview of Guardant Health

Guardant Health Online and Social Media Presence

Guardant Health News and Updates

Biotech company raises $360 million for cancer-detecting blood test

A California-based biotech company raised $360 million to fund a new early warning system that could detect cancer with a simple blood test. Guardant Health raised the funding for Guardant360, a blood test that measures genetic biomarkers for tumors, or a “liquid biopsy.” The blood would detect “cir…

Guardant Health adds $360 million to its war chest

 Guardant Health, a four-year-old, Redwood City, Ca.-based biotech company that sells blood tests to track and potentially detect cancer, has raised a whopping $360 million from investors, bringing its total funding to $550 million. SoftBank led the round, with participation from Sequoia Capital, Kh…

Cancer screening firm Guardant Health raises $360 million to sequence tumor DNA of 1 million patients

Guardant Health, a startup that’s been pushing to open a new front on the global war on cancer, has raised $360 million in a gargantuan round of funding led by a subsidiary of Japanese telecoms giant SoftBank, with participation from Sequoia Capital, Khosla Ventures, Lightspeed Venture Partners, Orb…

The secret ingredient that one successful VC’s winning bets all have in common

Bryan Roberts, a partner at the venture capital firm Venrock, has a portfolio most investors would envy. Nine companies in his health- and biotech-focused portfolio…

In liquid biopsy race, Freenome lands $65 million, led by Andreessen Horowitz

 Freenome, a two-year-old liquid biopsy diagnosis platform that detects the cell-free DNA sequencing of cancer, has raised a huge Series A round — $65 million — led by Andreessen Horowitz, which also led the company’s $5.5 million seed round less than a year ago. Other investors in the deal include …

There's a troubling trend brewing in how medical diagnostics startups are funded

Diagnostic and medical tools companies are getting a lot of attention from tech investors lately. Companies looking for new ways to screen the body for certain diseases — such as Genalyte, Grail and Guardant — have raised a total of $1.8 billion between 2015 and 2016, accord…
Show more

Guardant Health Company Life and Culture

You may also be interested in